Objective To observe the effect of electroacupuncture （EA） on egg quality of polycystic ovarian syndrome （PCOS） patients, and to explore its mechanism. Methods Two hundred patients who received in vitro fertilizat...Objective To observe the effect of electroacupuncture （EA） on egg quality of polycystic ovarian syndrome （PCOS） patients, and to explore its mechanism. Methods Two hundred patients who received in vitro fertilization-embryo transfer （IVF-ET） were divided into an EA group （102 cases） and a control group （98 cases） according to random number table. All the patients in the two groups were given Diane-35 and gonadotropin-releasing hormone agonist （GnRH-α） for ovarian hyperstimulation. Besides, EA intervention was applied to Shenshu （肾俞 BL 23）, Qihai （气海 GV 6）, Zusanli （足三里ST 36）, Sanyinjiao （三阴交 SP 6）, Neiguan （内关 PC 6） and Zigong （子宫 EX-CA1）, etc. in the EA group. Then egg quality, final outcome of pregnancy and levels of tumor necrosis factor-α （TNF-α） were compared between the two groups. Results （1） EA intervention significantly improved high quality embryo rate of PCOS patients （P〈0.05）, and clinical pregnancy rate was increased by 8.36%; （2） EA intervention significantly reduced the TNF-α levels of follicular fluid （13.61±15.46 vs 34.09±93.53, P〈0.05）; （3） TNF-α levels of serum and follicular fluid in the pregnancy group were lower than those of non-pregnancy group [pregnancy group： （53.91±63.32） pg/mL, （14.93±25.37） pg/mL, nonpregnancy group： （76.82 ± 82.96） pg/mL, （25.04 ± 35.79） pg/mL], and the differences were significant （both P〈0.05）. Conclusion EA improves egg quality of PCOS patients and increases the clinical pregnancy rate of IVF-ET, the mechanism may be related to TNF-α levels.展开更多
Aim:The cytokine receptor tumor necrosis factor receptor superfamily member 9(TNFRSF9)is mainly considered to be a co-stimulatory activation marker in hematopoietic cells.Several preclinical models have shown a dramat...Aim:The cytokine receptor tumor necrosis factor receptor superfamily member 9(TNFRSF9)is mainly considered to be a co-stimulatory activation marker in hematopoietic cells.Several preclinical models have shown a dramatic beneficial effect of treatment approaches targeting TNFRSF9 with agonistic antibodies.However,preliminary clinical phase I/II studies were stopped after the occurrence of several severe deleterious side effects.In a previous study,it was demonstrated that TNFRSF9 was strongly expressed by reactive astrocytes in primary central nervous system(CNS)tumors,but was largely absent from tumor or inflammatory cells.The aim of the present study was to address the cellular source of TNFRSF9 expression in the setting of human melanoma brain metastasis,a highly immunogenic tumor with a prominent tropism to the CNS.Methods:Melanoma brain metastasis was analyzed in a cohort of 78 patients by immunohistochemistry for TNFRSF9 and its expression was correlated with clinicopathological parameters including sex,age,survival,tumor size,number of tumor spots,and BRAF V600E expression status.Results:Tumor necrosis factor receptor superfamily member 9 was frequently expressed independently on both melanoma and endothelial cells.In addition,TNFRSF9 was also present on smooth muscle cells of larger vessels and on a subset of lymphomonocytic tumor infiltrates.No association between TNFRSF9 expression and patient survival or other clinicopathological parameters was seen.Of note,several cases showed a gradual increase in TNFRSF9 expression on tumor cells with increasing distance from blood vessels,an observation that might be linked to hypoxia-driven TNFRSF9 expression in tumor cells.Conclusion:The findings indicate that the cellular source of TNFRSF9 in melanoma brain metastasis largely exceeds the lymphomonocytic pool,and therefore further careful(re-)assessment of potential TNFRSF9 functions in cell types other than hematopoietic cells is needed.Furthermore,the hypothesis of hypoxia-driven TNFRSF9 expression in brain metastasis melanoma cells requires further functional testing.展开更多
基金Supported by the National Natural Science Foundation of China:30973790
文摘Objective To observe the effect of electroacupuncture （EA） on egg quality of polycystic ovarian syndrome （PCOS） patients, and to explore its mechanism. Methods Two hundred patients who received in vitro fertilization-embryo transfer （IVF-ET） were divided into an EA group （102 cases） and a control group （98 cases） according to random number table. All the patients in the two groups were given Diane-35 and gonadotropin-releasing hormone agonist （GnRH-α） for ovarian hyperstimulation. Besides, EA intervention was applied to Shenshu （肾俞 BL 23）, Qihai （气海 GV 6）, Zusanli （足三里ST 36）, Sanyinjiao （三阴交 SP 6）, Neiguan （内关 PC 6） and Zigong （子宫 EX-CA1）, etc. in the EA group. Then egg quality, final outcome of pregnancy and levels of tumor necrosis factor-α （TNF-α） were compared between the two groups. Results （1） EA intervention significantly improved high quality embryo rate of PCOS patients （P〈0.05）, and clinical pregnancy rate was increased by 8.36%; （2） EA intervention significantly reduced the TNF-α levels of follicular fluid （13.61±15.46 vs 34.09±93.53, P〈0.05）; （3） TNF-α levels of serum and follicular fluid in the pregnancy group were lower than those of non-pregnancy group [pregnancy group： （53.91±63.32） pg/mL, （14.93±25.37） pg/mL, nonpregnancy group： （76.82 ± 82.96） pg/mL, （25.04 ± 35.79） pg/mL], and the differences were significant （both P〈0.05）. Conclusion EA improves egg quality of PCOS patients and increases the clinical pregnancy rate of IVF-ET, the mechanism may be related to TNF-α levels.
文摘Aim:The cytokine receptor tumor necrosis factor receptor superfamily member 9(TNFRSF9)is mainly considered to be a co-stimulatory activation marker in hematopoietic cells.Several preclinical models have shown a dramatic beneficial effect of treatment approaches targeting TNFRSF9 with agonistic antibodies.However,preliminary clinical phase I/II studies were stopped after the occurrence of several severe deleterious side effects.In a previous study,it was demonstrated that TNFRSF9 was strongly expressed by reactive astrocytes in primary central nervous system(CNS)tumors,but was largely absent from tumor or inflammatory cells.The aim of the present study was to address the cellular source of TNFRSF9 expression in the setting of human melanoma brain metastasis,a highly immunogenic tumor with a prominent tropism to the CNS.Methods:Melanoma brain metastasis was analyzed in a cohort of 78 patients by immunohistochemistry for TNFRSF9 and its expression was correlated with clinicopathological parameters including sex,age,survival,tumor size,number of tumor spots,and BRAF V600E expression status.Results:Tumor necrosis factor receptor superfamily member 9 was frequently expressed independently on both melanoma and endothelial cells.In addition,TNFRSF9 was also present on smooth muscle cells of larger vessels and on a subset of lymphomonocytic tumor infiltrates.No association between TNFRSF9 expression and patient survival or other clinicopathological parameters was seen.Of note,several cases showed a gradual increase in TNFRSF9 expression on tumor cells with increasing distance from blood vessels,an observation that might be linked to hypoxia-driven TNFRSF9 expression in tumor cells.Conclusion:The findings indicate that the cellular source of TNFRSF9 in melanoma brain metastasis largely exceeds the lymphomonocytic pool,and therefore further careful(re-)assessment of potential TNFRSF9 functions in cell types other than hematopoietic cells is needed.Furthermore,the hypothesis of hypoxia-driven TNFRSF9 expression in brain metastasis melanoma cells requires further functional testing.
